Zacks Research Has Pessimistic Outlook of TMO Q2 Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Investment analysts at Zacks Research lowered their Q2 2025 earnings estimates for Thermo Fisher Scientific in a research note issued on Wednesday, May 14th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $5.22 for the quarter, down from their prior estimate of $5.59. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific's Q3 2025 earnings at $5.53 EPS, FY2025 earnings at $22.32 EPS and Q1 2027 earnings at $6.94 EPS.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company's revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter last year, the company posted $5.11 earnings per share.

Several other research analysts have also recently commented on the stock. Royal Bank of Canada lowered their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Barclays reduced their price target on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Raymond James reissued an "outperform" rating and issued a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Robert W. Baird dropped their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Finally, Stifel Nicolaus cut their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $607.43.

Thermo Fisher Scientific Stock Performance

TMO traded down $12.98 on Friday, reaching $400.77. The company had a trading volume of 1,708,694 shares, compared to its average volume of 1,845,266. The company's fifty day moving average is $449.99 and its 200 day moving average is $508.22. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a market cap of $151.29 billion, a P/E ratio of 24.23, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific has a fifty-two week low of $390.50 and a fifty-two week high of $627.88.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of institutional investors and hedge funds have recently modified their holdings of the company. Capital Investment Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 15.4% during the fourth quarter. Capital Investment Advisors LLC now owns 1,335 shares of the medical research company's stock worth $695,000 after purchasing an additional 178 shares during the period. SeaCrest Wealth Management LLC increased its position in Thermo Fisher Scientific by 26.7% in the 4th quarter. SeaCrest Wealth Management LLC now owns 1,743 shares of the medical research company's stock valued at $907,000 after acquiring an additional 367 shares during the period. Thurston Springer Miller Herd & Titak Inc. boosted its position in shares of Thermo Fisher Scientific by 74.7% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 166 shares of the medical research company's stock valued at $86,000 after purchasing an additional 71 shares in the last quarter. Pinnacle Bancorp Inc. lifted its position in shares of Thermo Fisher Scientific by 18.1% in the 4th quarter. Pinnacle Bancorp Inc. now owns 866 shares of the medical research company's stock valued at $451,000 after acquiring an additional 133 shares in the last quarter. Finally, HCR Wealth Advisors raised its holdings in shares of Thermo Fisher Scientific by 0.7% during the 4th quarter. HCR Wealth Advisors now owns 7,499 shares of the medical research company's stock valued at $3,902,000 after purchasing an additional 54 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at $59,506,950.58. This represents a 7.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at $5,759,736.32. The trade was a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,075 shares of company stock worth $7,305,942. Insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.